GKGhazaleh Khalili-Tanha

Ghazaleh Khalili-Tanha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ghazaleh Khalili-Tanha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Abdoljalal Marjani

    Metabolic disorders research center, Biochemistry and Biophysics department, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan Province, Iran

    1 shared publication
  • Amir Avan

    Basic Medical Sciences Institute, Mashhad University of Medical Sciences, Mashhad, Iran | Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran | Medical Genetics Research center, Mashhad University of Medical Sciences, Mashhad, Iran

    1 shared publication
  • Amir Avan

    Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    1 shared publication
  • Fatemeh Babaei

    Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    1 shared publication
  • Fereshteh Asgharzadeh

    Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad 13944-91388, Iran

    1 shared publication
  • Gordon A Ferns

    Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK

    1 shared publication

Latest Publications

  • Open Access

    The therapeutic potential of angiotensin-converting enzyme inhibitor enalapril to ameliorate muscle atrophy in a murine model

    by Sima Seifi, Seyedeh Elnaz Nazari, Amir Avan, Nima Khalili-Tanha, Fereshteh Asgharzadeh, Fatemeh Babaei, Ghazaleh Khalili-Tanha, Seyyedeh Zahra Asghari, Mahdieh Darroudi, Gordon A. Ferns, et al.

    Muscle atrophy due to limb immobilization and inactivity is a common consequence of many diseases and treatment processes. One of the systems activated in inflammatory conditions is the renin-angiotensin system (RAS). The present study was conducted with the aim of investigating the effects of one of the angiotensin-converting enzyme (ACE) inhibitors, enalapril, on improving muscle atrophy caused by immobility. The study was conducted in three groups: a control, an atrophy, and an atrophy group treated with enalapril on Balb/c mice. After tying a splint to cause atrophy in one of the legs, daily treatment with enalapril intraperitoneally (dissolved in DMSO) at a dose of 10 mg/kg/day was done for 7 days. On the eighth day, the splint was opened and half of the mice were evaluated. Then, in the recovery phase, treatment with enalapril was continued in the remaining mice for 10 days without a splint. At the end of each phase, the mice were examined for the muscle strength of the lower limb muscles, and histological and biochemical analyses were subsequently carried out. The tissue level of the oxidative stress index MDA was evaluated, which showed a significantly lower level in the enalapril group compared to the atrophy group (*P<0.1). Also, inflammatory factors in the enalapril group showed a decrease compared to the atrophy group. The strength of four limbs in the mice of the treatment group (-18.36 ± 1.70 %) was significantly higher than that of the atrophy group (-30.33 ± 3 %) at the end of the atrophy phase and also after 10 days of recovery. The results suggest that the use of enalapril that reduces the activation of angiotensin II-dependent pro-oxidant and pro-inflammatory pathways may improve the functional disorder and muscle necrosis in the murine model of muscle atrophy.


  • The Chance of COVID-19 Infection after Vaccination

    by Ghazaleh Khalili-Tanha, Majid Khazaei, Saman Soleimanpour, Gordon A Ferns, Amir Avan

    The outbreak of COVID-19 that was first reported in Wuhan, China, has constituted a new emerging epidemic that has spread around the world. There are some reports illustrating the patients getting re-infected after recovering from COVID-19. Here, we provide an overview of the biphasic cycle of COVID-19, genetic diversity, immune response, and a chance of reinfection after recovering from COVID-19. The new generation of COVID-19 is a highly contagious and pathogenic infection that can lead to acute respiratory distress syndrome. Whilst most patients suffer from a mild form of the disease, there is a rising concern that patients who recover from COVID-19 may be at risk of reinfection. The proportion of the infected population is increasing worldwide; meanwhile, the rate and concern of reinfection by the recovered population are still high. Moreover, there is little evidence on the chance of COVID-19 infection even after vaccination, which is around one percent or less. Although the hypothesis of zero reinfections after vaccination has not been clinically proven, further studies should be performed on the recovered class in clusters to study the progression of the exposure with the re-exposed subpopulations to estimate the possibilities of reinfection and, thereby, advocate the use of these antibodies for vaccine creation.